Treatment of HER2 positive breast cancer patients
Abstract
Breast cancer (BC) is the most common cancer in women. It is known already for years that BC is a heterogeneous disease. This has now been confirmed by BC gene signature by which at least four types of BC subtypes can be distinguished. Approximately 15 % of patients with BC have a »HER2 like« tumor. A distinctive feature of this subtype is an overexpression of HER2 protein and/or amplification of the HER2 gene. HER2 protein is a transmembrane receptor protein, which promotes tumor growth, replication, invasion and dissemination. Consequently, when diagnosed, HER2 positive tumors are usually larger, less-differentiated, and are more often accompanied by metastatic involvement of the axillary lymph nodes, as compared to HER2 negative tumors. Women with HER2 positive tumors are therefore at higher risk of cancer recurrence and death. With the introduction of targeted anti- HER2 therapy, the prognosis of HER2 disease has significantly improved. There are currently two antiHER2 drugs registered for use in general oncology practice. Trastuzumab is a monoclonal antibody directed toward the extracellular domain of HER2 protein. It is used for the treatment of metastatic BC and in adjuvant setting. It is more effective when combined with chemotherapy compared to monotherapy. Combined with chemotherapy, it prolongs time to progression and overall survival of patients with metastatic BC. A year of adjuvant treatment with trastuzumab reduces the risk of recurrence and death from BC by 50 % and 30 %, respectively. Lapatinib is a small molecule that binds to the intracellular domain of HER2 receptor. The drug is registered for the treatment of metastatic HER2 positive BC after failure to trastuzuamb therapy. Combined with chemotherapy or hormonal therapy, lapatinib prolongs time to progression in patients with metastatic BC. Several other antiHER2 drugs are currently under evaluation in clinical trials.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.